Cite
Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study.
MLA
Shih, Po-Cheng, et al. “Incidence and Risk Factors of Discontinuation of Tofacitinib and Biologic Disease-Modifying Anti-Rheumatic Drugs among Patients with Rheumatoid Arthritis: A Population-Based Cohort Study.” Clinical Rheumatology, Oct. 2024. EBSCOhost, https://doi.org/10.1007/s10067-024-07161-6.
APA
Shih, P.-C., Hung, P.-C., Leong, P.-Y., Hsu, J.-N., Yang, C.-C., Wei, J. C. C., & Chen, H.-H. (2024). Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-07161-6
Chicago
Shih, Po-Cheng, Po-Cheng Hung, Pui-Ying Leong, Jui-Ning Hsu, Chieh-Chun Yang, James Cheng Chung Wei, and Hsin-Hua Chen. 2024. “Incidence and Risk Factors of Discontinuation of Tofacitinib and Biologic Disease-Modifying Anti-Rheumatic Drugs among Patients with Rheumatoid Arthritis: A Population-Based Cohort Study.” Clinical Rheumatology, October. doi:10.1007/s10067-024-07161-6.